Home > Insider Trading > Filing (0001209191-21-037460)

Filing Details

Accession Number:: 0001209191-21-037460
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-02 20:52:57
Reporting Period:: 2021-02-01

Accepted Time:: 2021-06-02 20:52:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1845337	Day One Biopharmaceuticals Inc.	DAWN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1673237	Julie Papanek Grant	395 Oyster Point Blvd, Suite 217 South San Francisco CA 94080		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-06-01	7,328,497	$0.00	10,574,366	No	4	C	Indirect	By Canaan XI, L.P.
Common Stock	Acquisiton	2021-06-01	148,279	$0.00	10,722,645	No	4	C	Indirect	By Canaan XI, L.P.
Common Stock	Acquisiton	2021-06-01	13,000	$16.00	10,735,645	No	4	P	Indirect	By Canaan XI, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Canaan XI, L.P.
No	4	C	Indirect	By Canaan XI, L.P.
No	4	P	Indirect	By Canaan XI, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Acquisiton	2021-02-01	148,279	$0.00	148,279	$0.00
Common Stock	Stock Option (right to buy Common Stock)	Acquisiton	2021-05-26	63,000	$0.00	63,000	$16.00
Common Stock	Series A Preferred Stock	Disposition	2021-06-01	7,328,497	$0.00	7,328,497	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-06-01	148,279	$0.00	148,279	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
148,279		No	4	A	Indirect
63,000	2031-05-25	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	465,000	Direct

Footnotes

The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
Represents securities held by Canaan XI, L.P. ("Canaan LP"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any.
The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date.
The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021.
The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act.
The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.